These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 6897205

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.
    Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521
    [Abstract] [Full Text] [Related]

  • 3. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 4. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N, Lurie P, Mietlowski WL, Schilling A, Bennett JM, Horton J.
    Cancer Treat Rep; 1982 Jun 15; 66(6):1273-7. PubMed ID: 7044535
    [Abstract] [Full Text] [Related]

  • 5. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Kyle RA, Pajak TF, Henderson ES, Nawabi IU, Brunner K, Henry PH, McIntyre OR, Holland JF.
    Cancer Treat Rep; 1982 Mar 15; 66(3):451-6. PubMed ID: 7060034
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C, Sevilla F, Zapatero A, Blanco L, Sabán J, Serrano M, Serrano Ríos M.
    Rev Clin Esp; 1985 May 15; 176(8):392-5. PubMed ID: 3839590
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA.
    Cancer Treat Rep; 1984 Dec 15; 68(12):1439-46. PubMed ID: 6391662
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X, Monconduit M, Menard JF, Deshayes P, Grobois B, Tanguy A, Prevost E, Piguet H.
    Rev Rhum Mal Osteoartic; 1984 May 15; 51(5):263-7. PubMed ID: 6740189
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J, Kraj M, Rostkowska J, Maj S, Mariańska B, Mendek E, Roszkowski S, Kilian Z, Kołakowski L.
    Arch Immunol Ther Exp (Warsz); 1981 May 15; 29(2):145-53. PubMed ID: 7030265
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Polychemotherapy in multiple myeloma. The COMPA protocol].
    Vázquez-Villegas V, Delgado Lamas JL, Romero-García F, Rodríguez-Carrillo J, Medina-Ruiz F.
    Rev Invest Clin; 1989 May 15; 41(4):345-50. PubMed ID: 2698501
    [Abstract] [Full Text] [Related]

  • 16. [Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].
    Monti G, Cereda UG, Pessina E, De Micheli N, Grisetti GC, Invernizzi F.
    Minerva Med; 1983 Feb 11; 74(5):155-63. PubMed ID: 6828250
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
    Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B, Greipp PR.
    Cancer; 2006 May 01; 106(9):1958-66. PubMed ID: 16565956
    [Abstract] [Full Text] [Related]

  • 19. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
    Bataille R, Morlock G, Rosenberg F, Lopitaux R, Blotman F, Sany J, Ciurana AJ, Rampon S, Bussière JL, Simon L, Serre H.
    Rev Rhum Mal Osteoartic; 1980 Feb 01; 47(2):77-82. PubMed ID: 7361063
    [Abstract] [Full Text] [Related]

  • 20. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F, Lein JM, Pavlovsky S, Becherini JO, Pileggi JE, Micheo EQ, Jait C, Musso A, Suárez A, Pizzolato M.
    Cancer Treat Rep; 1980 Jan 01; 64(1):73-9. PubMed ID: 6991106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.